- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–20
of 20
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Interventions
- Antigen-Escalation Stage, Dose-Escalation Stage, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer
- Interventions
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine, Aldesleukin
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 70 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neoplasms
- Interventions
- GSK3845097, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Adaptimmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
- Conditions
- Solid Tumor, Leukemia, Lymphoma, Brain Tumor
- Interventions
- IMPACT, ESO
- Behavioral · Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Dayton, Ohio • Oklahoma City, Oklahoma
- Conditions
- HSV Infection
- Interventions
- Pritelivir, ESO and pritelivir
- Drug
- Lead sponsor
- AiCuris Anti-infective Cures AG
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
- Interventions
- ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, sirolimus, laboratory biomarker analysis, sargramostim
- Biological · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Barrett's Esophagus, Gastroesophageal Reflux Disease
- Interventions
- Not listed
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Chicago, Illinois • Rockford, Illinois + 7 more
- Conditions
- Neoplasms
- Interventions
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Houston, Texas
- Conditions
- Esophageal Varices
- Interventions
- PillCam Eso
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Plymouth, Minnesota • Portland, Oregon
- Conditions
- Ischemic Stroke
- Interventions
- Active Sphenopalatine Ganglion (SPG) Stimulation, Sham Sphenopalatine Ganglion (SPG) Stimulation
- Device
- Lead sponsor
- BrainsGate
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 7
- States / cities
- Sarasota, Florida • Winfield, Illinois • Greensboro, North Carolina + 3 more
- Conditions
- Melanoma
- Interventions
- CP 870,893, Peptides, Oncovir poly IC:LC
- Drug · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Solid Tumors, Sarcoma
- Interventions
- DS-2243a
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee
- Conditions
- Esophageal Lesion
- Interventions
- PillCam ESO Capsule Endoscope
- Diagnostic Test
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- CDX-1401, MPDL3280A
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- Ifinatamab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
- Conditions
- Cerebral Hemorrhage, Brain Hemorrhage, Cerebral Parenchymal Hemorrhage, Intracerebral Hemorrhage
- Interventions
- Artemis + Medical Management, Best Medical Management Alone (MM)
- Device · Other
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Mission Viejo, California + 22 more
- Conditions
- HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Interventions
- Aldesleukin, Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes, Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Dysphagia
- Interventions
- Laborie LMT Pharyngeal System (3.7 mm catheter), Medtronic ManoScan ESO HRM System (4.2 mm catheter)
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Refractory Anemia
- Interventions
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis, Nivolumab, Poly ICLC
- Biological · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Buffalo, New York